Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06886516 · ClinicalTrials.gov registry record · Early Phase 1
Apixaban in Thrombocytopenia
A Early Phase 1 study of Deep Vein Thrombosis and Thrombocytopenia, sponsored by Rushad Patell.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06886516: Recruiting Early Phase 1 study of Deep Vein Thrombosis and Thrombocytopenia, sponsored by Rushad Patell.
NCT06886516 is a Early Phase 1 study of Deep Vein Thrombosis and Thrombocytopenia that is actively recruiting participants, run by Rushad Patell. The registered enrollment target is 30 participants, below the 7,930-participant average among 24 other Deep Vein Thrombosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06886516, a Early Phase 1 study of Deep Vein Thrombosis and Thrombocytopenia, is actively recruiting participants, sponsored by Rushad Patell.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)
Primary Outcome
Study enrollment is defined as documentation of informed consent for participants approached.
Conditions Studied
Interventions
- DRUG Apixaban
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2028-07-01 |
| Phase | Early Phase 1 |
What NCT06886516 shows while recruiting
NCT06886516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 7,930-participant average among 24 other Deep Vein Thrombosis trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Deep Vein Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Apixaban is the first listed.
NCT06886516 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06886516 about?
NCT06886516 is a clinical study titled "Apixaban in Thrombocytopenia". This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see...
What is the current status of trial NCT06886516?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-28. Estimated completion is 2028-07-01.
What conditions does trial NCT06886516 study?
This clinical trial studies the following conditions: Deep Vein Thrombosis, Thrombocytopenia, Pulmonary Embolism and Thrombosis, Recurrent Venous Thromboembolism.
What interventions are being tested in trial NCT06886516?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT06886516?
This trial is sponsored by Rushad Patell, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06886516 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Deep Vein Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06886516's enrollment target sits among peer trials
30 23rd of 24 higher than 1 of 24 other Deep Vein Thrombosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Deep Vein Thrombosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.
RECRUITING
-
Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection
RECRUITING · NA
-
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
ACTIVE NOT RECRUITING · NA
-
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI